

Exercise of warrants increases capital of Fagron

Pursuant to Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, Fagron announces that 12,301 new shares have been issued as a result of the exercise of warrants. These newly issued shares are entitled to dividend as of the 2015 financial year.

The number of Fagron shares with voting rights is 31,443,661. The total number of voting rights (denominator) is 31,443,661. The share capital is € 322,217,493.06.

On 5 June 2015, there are 3,627 outstanding warrants under Warrant Plan 1. The total number of voting rights obtainable upon the exercise of these warrants is 3,627.

In the event of any discrepancy between the English translation and the original Dutch version of this press release, the latter shall prevail.

Fagron profile

Fagron is an innovative scientific pharmaceutical R&D company that is focused on optimising and innovating pharmaceutical compounding. Fagron offers Fagron Compounding Services, Fagron Trademarks and Fagron Compounding Essentials to pharmacies and hospitals in 32 countries worldwide. Pharmaceutical compounding is an essential part of pharmaceutical care that enables prescribers and pharmacists to fulfil the worldwide growing need for tailor-made medication. Fagron's own R&D department consists of 45 researchers and more than 300 pharmacists who are working continually on developing new concepts, vehicles and formulations to treat an increasing number of patients with tailor-made compounded medication. The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.

For further information

Marieke Palstra
Global Investor Relations Director
Tel. +31 88 33 11 213
marieke.palstra@fagron.com
investors.fagron.com

¹ This press release was sent out by Fagron NV and Fagron BV.

